Jane Ruppel

Jane Ruppel

Auto-generated profile, based on publicly available information

Jane Ruppel

BioAnalytical Sciences Department, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
JRJane Ruppel
Jane Ruppel
ABAnn Brady
Ann Brady
RERebecca Elliott
Rebecca Elliott
CLCecilia Leddy
Cecilia Leddy
MPMarco Palencia
Marco Palencia
EWEric Wakshull
Eric Wakshull
Anti-therapeutic antibodies (ATAs) may impact drug exposure and activity and induce immune complex mediated toxicity; therefore the accurate measurement of ATA is important for the analysis of drug safety and efficacy. Preexisting ATAs to the hinge region of anti-Delta like ligand 4 (anti-DLL4) F(ab′)2, a potential antitumor therapeutic, were detected in cynomolgus monkey serum, which presented a challenge in developing assays for detecting treatment induced ATA. A total ATA assay was developed using a bridging ELISA that detected both anti-CDR and anti-framework ATA including anti-hinge reactivity. A competition assay that could detect 500 ng/mL of anti-CDR ATA in the presence of preexisting ATA was also developed to determine ATA specific to the anti-DLL4 F(ab′)2CDR using anti-DLL4 F(ab′)2and a control F(ab′)2. We used these assay methods in a cynomolgus monkey in vivo study to successfully evaluate total and anti-CDR ATA. The preexisting anti-hinge reactivity was also observed to a lesser extent in human serum, and a similar approach could be applied for specific immunogenicity assessment in clinical trials.